What does it take to build not just one billion-dollar company, but seven and start again after losing it all? In this episode, Robert Wessman shares the mindset, discipline and foresight behind building one of the world’s most ambitious biosimilars platforms.

This week on Leading Beyond The Lab, Lawrence Rose sat down with Robert Wessman, Founder and Executive Chairman, with over 25 years of experience spanning global pharmaceuticals, generics, biosimilars and serial entrepreneurship.

In this episode, Robert Wessman covers:

(01:12) Why biologics dominate the future of pharmaceuticals and the urgent need to expand access through biosimilars, with treatment costs reaching up to $100,000 per patient annually

(04:10) Building seven companies including six unicorns, and scaling a global generics business across 80+ countries with over 16,500 employees

(12:32) The seven-pillar framework behind building high-performance culture, including vision setting, team alignment and execution discipline

(18:14) The importance of timing in biotech, and how starting too early or too late in biosimilars can determine success or failure

(38:16) Strategic foresight in action, from anticipating regulatory changes to building one of the largest biosimilars pipelines with over 30 products

This conversation offers a clear, experience-backed perspective on scaling in life sciences, building resilient organisations and making high-impact decisions in complex markets. If you are working in biotech, pharma or leadership, this episode provides practical insights worth applying.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@life_sciences

Robert Wessman

LinkedIn: https://www.linkedin.com/in/robert-wessman/

Lawrence Rose

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Introduction

00:46 The global cost challenge of biologics

01:12 Market dynamics and future of biosimilars

03:11 Origins of building multiple pharma companies

04:10 Scaling Actavis into a global leader

05:22 Repeatable frameworks for building companies

06:53 Execution, culture and operational excellence

10:01 Building Alvotech in Iceland

11:10 Hiring globally and building culture

12:32 The seven pillars of high-performance culture

15:28 Execution and accountability at scale

17:03 Scaling rapidly while maintaining culture

18:14 Timing the biosimilars market

19:27 Fundraising and early-stage selling

22:07 Building partnerships and licensing strategy

24:21 Manufacturing strategy and infrastructure

25:49 Business development and commercial model

27:11 Building global supply chains

28:23 Transitioning leadership roles

30:29 Evolution of CEO skillsets

32:03 AI and the future of work in pharma

34:03 Hiring for high-performance teams

36:33 Managing risk and operational challenges

37:07 Reducing development costs through foresight

38:16 Scaling pipeline strategy

40:25 Patent challenges and market barriers

42:19 Anticipating market shifts in biologics

44:11 Navigating setbacks and industry challenges

45:26 Market dynamics and global pricing pressures

47:08 Why Iceland as a strategic base

50:47 Attracting global talent to Iceland

53:09 Capital markets and disciplined growth

54:40 Risks of overfunding

55:04 Personal story and adversity

58:19 Near-death cycling accident

01:00:30 Recovery and resilience

01:05:55 Impact on mindset and life perspective

#LeadingBeyondTheLab #ARTOTalent #Biotech #Pharmaceuticals #Biosimilars #LifeSciences #Leadership

Hosted on Acast. See acast.com/privacy for more information.